~(131)I联合甲亢舒口服液治疗甲状腺功能亢进症临床观察

摘要

Objective To observe the treatment efficacy in patients with hyperthyroidism by ~(131) radioactive iodine in conjunction with Jiakangshu oral solution.Methods 465 cases with hyperthyroidism were divided into control group(n=235)and treatment group(n=230).In the treatment group on the basis of ~(131) iodine therapy plus service Jiakangshu oral solution.The contents of T_3,T_4,FT_3,FT_4,TSH were observed before and after treatment.Results The cure rate 74.7% in treatment group after treatment 12-month was higher than 65.1%(χ~2=3.94,P＜0.05),total effective rate 88.6% was higher than 80.4%(χ~2=3.90,P＜0.05).The contents of T_3,T_4,FT_3,FT_4,TSH drop,but TSH levels increased in two groups after 12 months with those before treatment(t=2.745,2.778,2.845,2.812,2.833,all P＜0.05).The contents of T_3,T_4,FT_3,FT_4 in treatment group decreased significantly compared with the control group after treatment 12 months(t=2.145,2.178,2.245,all P＜0.05).The negative conversion rate of TGAb,TMAb in the treatment group were significantly higher than control group(χ~2=3.98,3.88,all P＜0.05).Conclusion The treatment effecs are obvious in patients with hyperthyroidism by 131 radioactive iodine in conjunction with JiaKangShu oral solution.%目的 观察放射性~(131)I联合甲亢舒口服液治疗甲状腺功能亢进症(甲亢)的效果.方法 465例甲亢患者,随机分为对照组235例,治疗组230例.对照组采用~(131)I治疗,治疗组在对照组的基础上加服甲亢舒口服液,观察两组疗效及治疗前后血清T_3、T_4、FT_3、FT_4、TSH水平变化.结果 治疗组治疗后12个月的治愈率74.7%(172/230),高于对照组的65.1%(153/235)(χ~2=3.94,P＜0.05);治疗组总有效率88.6%,高于对照组的80.4%(χ~2=3.90,P＜0.05);两组治疗后12个月与治疗前比较,血清T3、T4、FT3、FT4水平明显下降,TSH水平上升(t=2.745、2.778、2.845、2.812、2.833,均P＜0.05),且治疗组治疗12个月后T_4、FT_3、FT_4水平较对照组的下降更明显(t=2.145、2.178、2.245,均P＜0.05);治疗组血清抗甲状腺球蛋白抗体、抗甲状腺微粒体抗体转阴率均显著高于对照组(χ~2=3.98、3.88,均P＜0.05).结论 甲亢舒口服液联合~(131)I治疗甲亢效果显著.